CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy
Since tumors are often infiltrated by macrophages, it would be advantageous to turn these types of cells into cytotoxic effector cells. Here, we have designed a novel bispecific antibody (BsAb) that targets both tumor antigen (CD20) and the FcαRI receptor (CD89). This antibody could be used to lyse...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Taylor & Francis Group
2018-01-01
|
| Ráidu: | OncoImmunology |
| Fáttát: | |
| Liŋkkat: | http://dx.doi.org/10.1080/2162402X.2017.1380142 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|